Page 2437 - Williams Hematology ( PDFDrive )

2408 Index Index 2409

Bosutinib Bromodomain and extraterminal (BET) Busulfan
adverse effects, 339t, 341, 1451t inhibitors, 170, 338 adverse effects, 330
for chronic myelogenous leukemia, 339t, Bronzed diabetes, 639. See also for chronic myelogenous leukemia, 1459
1451t, 1454, 1457–1458, 1466 Hemochromatosis for essential thrombocythemia, 1313t,
comparison with other tyrosine kinase Brown recluse spider bites, 836 1314
inhibitors, 1451t Brucella/brucellosis, 1062, 1268 high-dose, before hematopoietic cell
drug interactions, 339t, 1451t Bruising, 6, 1987 transplantation, 331t, 332, 360,
pharmacology, 339t Bruton tyrosine kinase (BTK), 1144, 1212, 1399
structure, 340f 1529, 1712, 1713, 1787 mechanism of action, 329
Botrocetin, 1867, 1868 Bruton tyrosine kinase (BTK) inhibitors, 342. for polycythemia vera, 1298t, 1299
Boyadjiev-Jabs syndrome, 567 See also Ibrutinib
1,3-BPG (1,3-Bisphosphoglycerate), 692, BTCC-1. See CD9 C
695 BTK, 235t, 993 C1 (C ) esterase inhibitor, 290, 839, 1845,
1
2,3-BPG. See 2,3-Bisphosphoglycerate BTRC, 1711 2308
(2,3-BPG) Budd-Chiari syndrome, 575t, 581, 1293 C1q receptors, 284, 1873
BPGM, 695 Buffy-coat method, 2386, 2386f C3. See CD11b
BPI (bacterial permeability-increasing Burkholderia cepacia, 1030, 1033 C3, 2259t
protein), 106–107, 1011, 1012t, Burkitt lymphoma (BL), 1671–1676 C3a, 290, 1932, 2374
1013 cell metabolism in, 199 C3AR1, 1643
Bradykinin, 286t, 289, 2374 clinical features, 1672 C3b, 290, 1017, 2260, 2374
Bradyrhizobium enterica, 357 course and prognosis, 1676 C3b-coated erythrocytes, 829
BRAF, 232t, 233t, 1103, 1108, 1111, 1737, definition and history, 1671 C3bi, 829, 831
1759 differential diagnosis, 1674 C3 convertases, 289f, 290
BRAF inhibitors epidemiology, 1570, 1671 C3 receptors, 1015
for hairy cell leukemia, 1559 etiology and pathogenesis C4, 2000
for Langerhans cell histiocytosis, 1107 chromosomal abnormalities, 184t, 186f, C4b-binding protein, 1958, 2202
BRAF V600E, 1554 187, 1496t, 1576, 1596, 1672 C5a, 283, 942, 1932, 1972
Brain injury/tumors. See Neurologic disease/ Epstein-Barr virus infection and C5a receptor, 1015
symptoms malaria, 1265, 1573, 1672 C5 convertases, 289f, 290
BRCA2, 529 gene mutations, 1496t, 1672 C9, 2000
BRCC3, 1346t HIV-associated, 187, 1244f, 1245, 1247, C15ORF41, 565
Breakpoint, 175t 1672, 1676 Cabot rings, 467f, 468, 594
Breast, primary lymphomas in, 1583 laboratory features Cachexin/cachectin. See Tumor necrosis
Breast cancer blood and marrow, 1673, 1673f factor (TNF)-α
disseminated intravascular coagulation in, cytogenetics, 1674 Cadherins, 68
2207 Epstein-Barr virus studies, 1674 CAFC (cobblestone area-forming cell), 260
Hodgkin lymphoma treatment and, histopathology, 1496t, 1596, 1597f, 1598, Café-au-lait spots, 529, 1471
1617–1618 1673–1674, 1673f CAGE questions, 6
secondary acute myelogenous leukemia immunophenotype, 1674 Calciphylaxis, cutaneous, 2101–2102
and, 1407 staging, 1577f, 1673t Calcium, in platelet activation, 1836, 1837f,
Breast implants, 1698 therapy, 1675, 1675t 1881–1882
Brentuximab vedotin, 346 tumor lysis syndrome in, 1675 Calcium channel blockers, 2078
for anaplastic large cell lymphoma, 1699 Burns Calcium-dependent proteases (Calpains),
for CD30+ lymphoproliferative disorders, disseminated intravascular coagulation 1842, 1848, 1883
1687 and, 2208 Calcium (Ca ) entry channel deficiency, 1221
2+
dose and toxicity, 343t, 1687 hemolysis and, 809, 810f CALDAGGEF1, 2060
for Hodgkin lymphoma, 1248, 1614, 1616 Burr cells. See Echinocytes CalDAG-GEF1 deficiency, 2057
for mycosis fungoides, 1687 Burst-forming unit-erythroid (BFU-E) Caldesmon, in platelet cytoskeleton, 1832t
for peripheral T-cell lymphoma, 1696, in aplastic anemia and, 514 Calf vein thrombosis, 2273
1696t development, 63, 461, 462 CALLA. See CD10 (CALLA)
for primary effusion lymphoma, 1247 in erythropoiesis, 480, 480f, 483f Calmodulin, 1833t
BRG/BAF-associated factors (BAF) complex, progenitors, 270 CALR, 229t, 1278, 1307, 1308f, 1310, 1321
166, 166f in yolk sac and fetus, 100, 100f Calreticulin, 1836
Brill-Symmers disease, 1569 Burst-forming unit-erythroid (BFU-E) cAMP (cyclic adenosine monophosphate),
Bromodomain and extraterminal (BET)- precursors, polycythemia vera and, 404–405
family, 169 1292 CAMP (hCAP-18, LL-37), 1012t, 1013

Kaushansky_index_p2393-2506.indd 2408 9/21/15 3:21 PM